New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

Jul 19, 2016

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

Read Article

MMJ Now Licensed to Grow Medical Cannabis

Jul 5, 2016

There are just 32 companies in Canada that have a license to grow medical cannabis – and MMJ PhytoTech, Ltd (ASX:MMJ) has just officially joined their ranks – the first ASX listed company to do so. A licence to grow medicinal cannabis is not easy to get your hands on in Canada – over 1200 companies have tried, and over 1000 have failed or given up – indicating the stringent nature of the country’s health regulators.

Read Article

Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX Stock?

Apr 20, 2016

As humans continue to live longer, certain diseases start to become more apparent, causing widespread concern for the elderly and their families. One of them is Alzheimer’s disease (AD) – a horrific disease that starts off with short-term memory loss and gradually progresses to severe memory failure including forgetting your own children and family.

Read Article

MMJ Set to Boost Medical Cannabis Production Capacity by 1000%?

Apr 1, 2016

The market for medical cannabis is gradually moving out of the wilderness and onto government radars. The once forgotten medicine is currently being re-evaluated and reclassified in the US, Australia and Europe as its positive effect on a range of ailments is finally being rediscovered and decriminalised by governments across the globe.

Read Article
Be alerted as soon as an article is released - Join our mailing list (FREE)
  • close

Are you a sophisticated investor?